R&D Trends: Parkinson%s Disease – Pipeline swells but a paradigm shift is unlikely in the mid-term

• Publication date: June 2012
• Report size: 73 pages

Since early 2011, R&D efforts in Parkinson’s disease have been met with mixed success. In Q1 2012, the US FDA re-approved UCB’s Neupro (rotigotine patch), and accepted the New Drug Application filing for Impax/GSK’s IPX066 for idiopathic Parkinson’s disease. Meanwhile, the development of eight late-stage pipeline candidates has been discontinued due to lacklustre efficacy....

Since early 2011, R&D efforts in Parkinson’s disease have been met with mixed success. In Q1 2012, the US FDA re-approved UCB’s Neupro (rotigotine patch), and accepted the New Drug Application filing for Impax/GSK’s IPX066 for idiopathic Parkinson’s disease. Meanwhile, the development of eight late-stage pipeline candidates has been discontinued due to lacklustre efficacy.Understand key dynamics in the R&D pipeline for new Parkinson’s disease therapies.Benchmark novel and existing therapies using the target product profile identified by Datamonitor.Support R&D decision making by evaluating current and future Parkinson’s disease clinical trial designs.Evaluate the most promising new pharmacological targets in early-stage development.Access Datamonitor's prediction of how the Parkinson’s disease treatment landscape may change in the next 20 years.Since December 2010, the Parkinson’s disease pipeline has grown by 28% to a sizeable 168 individual programs. While the vast majority (67%) of the pipeline candidates are in the preclinical stage, many of these will fail to progress into later stages of development due to the high rate of attrition.Despite targeting a wide variety of mechanisms, the majority of pipeline candidates targeting well established mechanisms are reformulations. Unless additional clinical differentiation can be demonstrated, these products will struggle to pose strong competition to current market leading agents.High placebo response and poor recruitment of patients are just some of the many challenges inherent in Parkinson’s disease clinical trials. Better understanding the etiology of the condition and the development of biomarkers will aid the development of novel therapies. The identification of a disease modifying treatment remains the ultimate goal.What are the key trends in the Parkinson’s disease pipeline?How has the pipeline evolved since December 2010?What is the clinical gold standard and how do new candidates have to compare to this to successfully penetrate the market?What are the main challenges inherent in the conduct of Parkinson’s disease clinical trials and what can be done to overcome these?How will understanding the etiology and biomarkers aid early diagnosis and direct the development of disease-modifying drugs in the future?

Drug Discovery And Development Industry in the United States

Clinical Trial in United States

United States Phase I Clinical Trials

• $ 250
• Industry data
• January 2013

Yearly, From 2006 To 2010
By Business Monitor International
Source: ClinicalTrials.gov, BMI. N.B. Sourced by date of initial registration.

• Industries : Drug Discovery and Development
• Countries : United States

United States Total Clinical Trials

• $ 250
• Industry data
• January 2013

Yearly, From 2006 To 2010
By Business Monitor International
Source: ClinicalTrials.gov, BMI. N.B. Sourced by date of initial registration.

• Industries : Drug Discovery and Development
• Countries : United States

United States Phase Ii Clinical Trials

• $ 250
• Industry data
• January 2013

Yearly, From 2006 To 2010
By Business Monitor International
Source: ClinicalTrials.gov, BMI. N.B. Sourced by date of initial registration.

• Industries : Drug Discovery and Development
• Countries : United States

United States Phase Iii Clinical Trials

• $ 250
• Industry data
• January 2013

Yearly, From 2006 To 2010
By Business Monitor International
Source: ClinicalTrials.gov, BMI. N.B. Sourced by date of initial registration.

• Industries : Drug Discovery and Development
• Countries : United States

United States Phase Iv Clinical Trials

• $ 250
• Industry data
• January 2013

Yearly, From 2006 To 2010
By Business Monitor International
Source: ClinicalTrials.gov, BMI. N.B. Sourced by date of initial registration.

• Industries : Drug Discovery and Development
• Countries : United States